Related Experiment Videos
Platelet inhibitors and antioxidant vitamins in cardiovascular disease
1Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215.
Insights
Aspirin use can reduce vascular events in patients with existing cardiovascular disease. Ongoing trials are investigating the role of antioxidant vitamins and aspirin in preventing cardiovascular disease in broader populations.
Area of Science:
- Cardiovascular Disease Research
- Preventive Medicine
- Pharmacology
Background:
- Platelet inhibition (e.g., aspirin) and antioxidant vitamins are researched for cardiovascular disease (CVD) risk reduction.
- Observational studies suggest high antioxidant vitamin intake correlates with lower CVD risk, but confounding factors are possible.
- Randomized trials are crucial to confirm these associations and establish causality.
Purpose of the Study:
- To review the evidence for aspirin's efficacy in secondary and primary prevention of CVD.
- To examine the potential benefits of antioxidant vitamins in CVD prevention.
- To highlight the ongoing research evaluating these interventions.
Main Methods:
- Analysis of data from large-scale randomized trials on aspirin use.
- Review of observational studies and ongoing randomized trials for antioxidant vitamins.
- Evaluation of evidence for both secondary and primary CVD prevention.
Main Results:
- Aspirin is effective in reducing vascular events in patients with established CVD and acute myocardial infarction.
- Primary prevention data for aspirin is mixed; ongoing trials like the Women's Health Study will provide more clarity.
- Observational data suggests a link between antioxidant vitamins and reduced CVD risk, but requires confirmation through randomized trials.
Conclusions:
- Aspirin demonstrates clear benefits in secondary CVD prevention.
- The role of aspirin in primary prevention requires further investigation, particularly in women.
- Randomized trials are essential to validate the cardiovascular benefits of antioxidant vitamins.
Abstract:
Considerable research attention has focused on the possible roles of platelet inhibition, principally using aspirin, and antioxidant vitamins in reducing the risks of cardiovascular disease. Data from large-scale randomized trials indicate that aspirin reduces subsequent vascular events among patients with prior myocardial infarction, stroke, transient ischemic attacks, or unstable angina, as well as among patients with acute evolving myocardial infarction. In primary prevention trials, the Physicians' Health Study showed a clear benefit in decreasing risk of a first myocardial infarction in men; the data on stroke and total number of deaths from vascular causes are inadequate. The Women's Health Study, a trial now under way among apparently healthy women, will provide direct evidence on the balance of risks and benefits of aspirin in primary prevention. Antioxidant vitamins are hypothesized to decrease cardiovascular disease risk by several mechanisms, including inhibition of oxidation of low-density lipoprotein cholesterol and decreasing uptake into the coronary endothelium. Promising results have emerged from observational studies, which show that people with high intakes of antioxidant vitamins through diet or supplements have lowered risks of cardiovascular disease; however, unknown or unmeasured factors associated with high antioxidant vitamin intake may explain all or part of the observed associations. Randomized trials to provide reliable data are now ongoing among apparently healthy men and women, as well as among survivors of prior cardiovascular disease events.